ATE253361T1 - Mittel zur gesteuerten freisetzung von paroxetin - Google Patents

Mittel zur gesteuerten freisetzung von paroxetin

Info

Publication number: ATE253361T1
Authority: AT; Austria
Prior art keywords: paroxetine; agents; controlled release; release; controlled
Prior art date: 1995-07-20

Application number

AT96926388T

Other languages

English (en)

Inventor

Graham S Leonard

David P Edler

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-07-20

Filing date

1996-07-19

Publication date

2003-11-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10777960&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE253361(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-07-19 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2003-11-15 Application granted granted Critical

2003-11-15 Publication of ATE253361T1 publication Critical patent/ATE253361T1/de

Links

AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 title 1
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 title 1
238000013270 controlled release Methods 0.000 title 1
229960002296 paroxetine Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)
Polyurethanes Or Polyureas (AREA)

AT96926388T 1995-07-20 1996-07-19 Mittel zur gesteuerten freisetzung von paroxetin ATE253361T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9514842.5A GB9514842D0 (en)	1995-07-20	1995-07-20	Novel formulation
PCT/EP1996/003252 WO1997003670A1 (en)	1995-07-20	1996-07-19	Paroxetine controlled release compositions

Publications (1)

Publication Number	Publication Date
ATE253361T1 true ATE253361T1 (de)	2003-11-15

Family

ID=10777960

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96926388T ATE253361T1 (de)	1995-07-20	1996-07-19	Mittel zur gesteuerten freisetzung von paroxetin

Country Status (40)

Country	Link
EP (2)	EP1382337A1 (de)
JP (2)	JP3922392B2 (de)
KR (1)	KR100468351B1 (de)
CN (2)	CN1117567C (de)
AP (1)	AP1052A (de)
AR (1)	AR003463A1 (de)
AT (1)	ATE253361T1 (de)
AU (1)	AU6659196A (de)
BG (1)	BG64076B1 (de)
BR (1)	BR9609857A (de)
CA (2)	CA2445678C (de)
CY (1)	CY2408B1 (de)
CZ (1)	CZ294110B6 (de)
DE (1)	DE69630603T3 (de)
DK (1)	DK0839039T4 (de)
DZ (1)	DZ2074A1 (de)
EA (2)	EA003508B1 (de)
EG (1)	EG23934A (de)
ES (1)	ES2208757T5 (de)
GB (1)	GB9514842D0 (de)
HU (1)	HU228853B1 (de)
IL (1)	IL122940A0 (de)
MA (1)	MA23942A1 (de)
MX (1)	MX9800571A (de)
MY (1)	MY141373A (de)
NO (1)	NO315637B1 (de)
NZ (1)	NZ315006A (de)
OA (1)	OA10652A (de)
PE (1)	PE16098A1 (de)
PL (1)	PL184987B1 (de)
PT (1)	PT839039E (de)
RO (1)	RO119119B1 (de)
SI (1)	SI0839039T2 (de)
SK (1)	SK284117B6 (de)
TR (1)	TR199800077T1 (de)
TW (1)	TW464513B (de)
UA (1)	UA68328C2 (de)
UY (3)	UY24288A1 (de)
WO (1)	WO1997003670A1 (de)
ZA (1)	ZA966148B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6638948B1 (en)	1996-09-09	2003-10-28	Pentech Pharmaceuticals, Inc.	Amorphous paroxetine composition
US5910319A (en) *	1997-05-29	1999-06-08	Eli Lilly And Company	Fluoxetine enteric pellets and methods for their preparation and use
EE03970B1 (et)	1997-06-10	2003-02-17	Synthon B.V.	4-fenüülpiperidiinühend, selle valmistamine ja kasutamine ning seda sisaldav ravim
US5955475A (en) *	1997-06-30	1999-09-21	Endo Pharmaceuticals Inc.	Process for manufacturing paroxetine solid dispersions
HUP0002296A3 (en)	1997-07-01	2001-11-28	Pfizer	Sertraline salts and sustained-release dosage forms of sertraline
GB9808479D0 (en) *	1998-04-22	1998-06-17	Smithkline Beecham Plc	Method of treatment
CH689805A8 (fr) *	1998-07-02	2000-02-29	Smithkline Beecham Plc	Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
US6139875A (en) *	1998-09-29	2000-10-31	Eastman Chemical Company	Aqueous enteric coating composition and low gastric permeability enteric coating
ATE311883T1 (de)	1999-03-12	2005-12-15	Aesica Pharmaceuticals Ltd	Stabile pharmazeutische anwendungsform für paroxetin-anhydrat
IE990406A1 (en)	1999-05-20	2000-12-27	Elan Corp Plc	Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
EP1178780B1 (de) *	1999-05-20	2007-07-18	ELAN CORPORATION, Plc	Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme
ES2159260B1 (es) *	1999-06-22	2002-05-01	Smithkline Beechan Plc	Nueva composicion de metanosulfonato de paroxetina
WO2000078290A2 (en) *	1999-06-22	2000-12-28	Smithkline Beecham P.L.C.	Pharmaceutical composition comprising a salt of paroxetine
ES2162560B1 (es) *	1999-06-25	2002-07-16	Rodriguez Concepcion Pena	Uso de fluoxetina, paroxetina y otros isrs para la fabricacion de medicamentos con el fin de aumentar la capacidad de abstenerse de substancias o actividades que crean dependencia.
AR030557A1 (es)	2000-04-14	2003-08-27	Jagotec Ag	Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6482440B2 (en) *	2000-09-21	2002-11-19	Phase 2 Discovery, Inc.	Long acting antidepressant microparticles
CA2457385A1 (en) *	2001-08-06	2003-02-20	Dr. Reddy's Laboratories Ltd.	Improved enteric formulation of fluoxetin
GB2392385A (en) *	2002-09-02	2004-03-03	Cipla Ltd	Pharmaceutical preparations comprising a 5HT uptake inhibitor and a homopolymer or copolymer of N-vinyl pyrrolidone
WO2005044262A1 (en)	2003-10-29	2005-05-19	Wyeth	Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
EP1734920A2 (de) *	2004-02-13	2006-12-27	Neuromolecular Inc.	Kombination aus einem nmda-rezeptor-antagonisten und einem mao-hemmer oder einem gadph-hemmer zur behandlung von psychiatrischen erkrankungen
WO2005107716A1 (en) *	2004-03-25	2005-11-17	Cadila Healthcare Limited	Controlled release paroxetine-containing tablets based on a core and a coating
WO2007015270A2 (en) *	2005-08-02	2007-02-08	Lupin Limited	Novel controlled release compositions of selective serotonin reuptake inhibitors
KR100591142B1 (ko) *	2005-11-04	2006-06-20	지엘팜텍 주식회사	파록세틴을 활성물질로 함유하는 장용성 서방형 정제
US20090130206A1 (en) *	2006-05-09	2009-05-21	Umesh Nandkumar Khatavkar	Controlled Release Compositions of an Antidepressant Agent
KR100885029B1 (ko) *	2007-02-07	2009-02-23	지엘팜텍 주식회사	경구투여용 서방성 삼중정제
WO2009006299A2 (en) *	2007-06-29	2009-01-08	Dr. Reddy's Laboratories Ltd.	Multi-particulate systems
JP5647519B2 (ja)	2007-09-13	2014-12-24	コンサートファーマシューティカルズインコーポレイテッド	重水素化カテコールおよびベンゾ［ｄ］［１，３］ジオキソールおよびその誘導体の合成
TW201010743A (en) *	2008-09-05	2010-03-16	Otsuka Pharma Co Ltd	Pharmaceutical solid preparation
GEP20135950B (en) *	2009-08-24	2013-10-25	H Lundbeck As	New compositions containing 1-[2-(2,4-dimethyl-phenylsulfa-nyl)-phenyl]piperazine
CN103371982A (zh) *	2012-04-20	2013-10-30	王进京	盐酸帕罗西汀肠溶控释片新型处方组成及制备方法
IN2015MN00005A (de) *	2012-07-09	2015-10-16	Unilever Plc
CN103550182B (zh) *	2013-10-29	2015-04-08	吉林省东盟制药有限公司	一种肠溶缓释组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8626936D0 (en) *	1986-11-11	1986-12-10	Ferrosan As	Treatment
MC2025A1 (fr) *	1988-04-20	1990-04-25	Asta Pharma Ag	Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
IT1237904B (it) *	1989-12-14	1993-06-18	Ubaldo Conte	Compresse a rilascio a velocita' controllata delle sostanze attive
JPH0436237A (ja) *	1990-06-01	1992-02-06	Taiho Yakuhin Kogyo Kk	抗腫瘍性複合製剤
AU8444291A (en) *	1990-08-21	1992-03-17	Oramed, Inc.	Controlled release formulations and method
JPH06502854A (ja) *	1990-11-24	1994-03-31	ビーチャム・グループ・パブリック・リミテッド・カンパニー	老年痴呆、過食症、片頭痛または食欲不振の治療用のパロキセチンの使用
EP0720478A1 (de) *	1991-05-07	1996-07-10	Dynagen, Inc.	Gesteuertes abgabesystem mit verzögerter freisetzung zur raucherentwöhnung
JPH05139964A (ja) *	1991-11-14	1993-06-08	Takada Seiyaku Kk	塩酸メキシレチン腸溶性製剤
EP0654263B1 (de) *	1993-11-23	2002-01-23	Euro-Celtique S.A.	Verfahren zur Herstellung einer Arzneizusammensetzung mit verzögerter Wirkstoffabgabe
IT1274241B (it) *	1993-12-03	1997-07-15	Smithkline Beecham Farma	Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
CA2143070C (en) *	1994-02-22	2001-12-18	Pankaj Modi	Oral controlled release liquid suspension pharmaceutical formulation
GB9422154D0 (en) *	1994-11-03	1994-12-21	Euro Celtique Sa	Pharmaceutical compositions and method of producing the same
WO1996031197A1 (en) *	1995-04-03	1996-10-10	Abbott Laboratories	Homogeneous mixtures of low temperature-melting drugs and additives for controlled release

1995
- 1995-07-20 GB GBGB9514842.5A patent/GB9514842D0/en active Pending
1996
- 1996-07-17 DZ DZ960118A patent/DZ2074A1/fr active
- 1996-07-18 MY MYPI96002956A patent/MY141373A/en unknown
- 1996-07-18 MA MA24317A patent/MA23942A1/fr unknown
- 1996-07-18 EG EG68296A patent/EG23934A/xx active
- 1996-07-18 AR ARP960103639A patent/AR003463A1/es not_active Application Discontinuation
- 1996-07-19 CA CA002445678A patent/CA2445678C/en not_active Expired - Lifetime
- 1996-07-19 EP EP03078259A patent/EP1382337A1/de not_active Withdrawn
- 1996-07-19 AP APAP/P/1998/001177A patent/AP1052A/en active
- 1996-07-19 CN CN96196819A patent/CN1117567C/zh not_active Expired - Lifetime
- 1996-07-19 EP EP96926388A patent/EP0839039B2/de not_active Expired - Lifetime
- 1996-07-19 PT PT96926388T patent/PT839039E/pt unknown
- 1996-07-19 KR KR10-1998-0700380A patent/KR100468351B1/ko not_active Expired - Lifetime
- 1996-07-19 CA CA002227298A patent/CA2227298C/en not_active Expired - Lifetime
- 1996-07-19 HU HU9900299A patent/HU228853B1/hu unknown
- 1996-07-19 TW TW085108758A patent/TW464513B/zh not_active IP Right Cessation
- 1996-07-19 JP JP50632597A patent/JP3922392B2/ja not_active Expired - Lifetime
- 1996-07-19 ES ES96926388T patent/ES2208757T5/es not_active Expired - Lifetime
- 1996-07-19 BR BR9609857A patent/BR9609857A/pt not_active Application Discontinuation
- 1996-07-19 PE PE1996000548A patent/PE16098A1/es not_active IP Right Cessation
- 1996-07-19 IL IL12294096A patent/IL122940A0/xx not_active IP Right Cessation
- 1996-07-19 DK DK96926388T patent/DK0839039T4/da active
- 1996-07-19 AT AT96926388T patent/ATE253361T1/de active
- 1996-07-19 ZA ZA9606148A patent/ZA966148B/xx unknown
- 1996-07-19 WO PCT/EP1996/003252 patent/WO1997003670A1/en not_active Ceased
- 1996-07-19 NZ NZ315006A patent/NZ315006A/xx not_active IP Right Cessation
- 1996-07-19 UA UA98010283A patent/UA68328C2/uk unknown
- 1996-07-19 SK SK53-98A patent/SK284117B6/sk not_active IP Right Cessation
- 1996-07-19 PL PL96324553A patent/PL184987B1/pl unknown
- 1996-07-19 TR TR1998/00077T patent/TR199800077T1/xx unknown
- 1996-07-19 EA EA200100022A patent/EA003508B1/ru not_active IP Right Cessation
- 1996-07-19 CZ CZ1998183A patent/CZ294110B6/cs not_active IP Right Cessation
- 1996-07-19 RO RO98-00082A patent/RO119119B1/ro unknown
- 1996-07-19 DE DE69630603T patent/DE69630603T3/de not_active Expired - Lifetime
- 1996-07-19 EA EA199800140A patent/EA003775B1/ru not_active IP Right Cessation
- 1996-07-19 UY UY24288A patent/UY24288A1/es not_active IP Right Cessation
- 1996-07-19 MX MX9800571A patent/MX9800571A/es active IP Right Grant
- 1996-07-19 SI SI9630661T patent/SI0839039T2/sl unknown
- 1996-07-19 AU AU66591/96A patent/AU6659196A/en not_active Abandoned
- 1996-07-19 CN CNB031490468A patent/CN1282456C/zh not_active Expired - Lifetime
1997
- 1997-01-10 UY UY24436A patent/UY24436A1/es not_active IP Right Cessation
1998
- 1998-01-19 NO NO19980240A patent/NO315637B1/no not_active IP Right Cessation
- 1998-01-20 OA OA9800005A patent/OA10652A/en unknown
- 1998-02-17 BG BG102259A patent/BG64076B1/bg unknown
2000
- 2000-07-13 UY UY26242A patent/UY26242A1/es not_active Application Discontinuation
2004
- 2004-03-15 CY CY0400019A patent/CY2408B1/xx unknown
2006
- 2006-04-27 JP JP2006123731A patent/JP2006265258A/ja active Pending

Also Published As

Publication number	Publication date
SK5398A3 (en)	1998-07-08
CN1515257A (zh)	2004-07-28
NO315637B1 (no)	2003-10-06
ES2208757T3 (es)	2004-06-16
IL122940A0 (en)	1998-08-16
MX9800571A (es)	1998-04-30
TR199800077T1 (xx)	1998-05-21
DE69630603T2 (de)	2004-09-23
WO1997003670A1 (en)	1997-02-06
UY24436A1 (es)	2001-08-27
TW464513B (en)	2001-11-21
NZ315006A (en)	2000-01-28
UY26242A1 (es)	2001-01-31
JP2006265258A (ja)	2006-10-05
CZ18398A3 (cs)	1998-06-17
BR9609857A (pt)	1999-03-16
KR19990029076A (ko)	1999-04-15
EA003775B1 (ru)	2003-08-28
EP0839039A1 (de)	1998-05-06
UA68328C2 (en)	2004-08-16
NO980240L (no)	1998-01-20
EG23934A (en)	2008-01-14
EP1382337A1 (de)	2004-01-21
EA003508B1 (ru)	2003-06-26
CA2227298C (en)	2003-12-09
EA200100022A1 (ru)	2001-06-25
HU228853B1 (en)	2013-06-28
JPH11509539A (ja)	1999-08-24
CA2227298A1 (en)	1997-02-06
EA199800140A1 (ru)	1998-10-29
PL184987B1 (pl)	2003-01-31
BG102259A (en)	1998-09-30
KR100468351B1 (ko)	2005-03-16
PT839039E (pt)	2004-03-31
HUP9900299A3 (en)	1999-11-29
CA2445678C (en)	2009-11-24
UY24288A1 (es)	1997-01-16
AR003463A1 (es)	1998-08-05
EP0839039B1 (de)	2003-11-05
CN1282456C (zh)	2006-11-01
RO119119B1 (ro)	2004-04-30
CY2408B1 (en)	2004-09-10
AU6659196A (en)	1997-02-18
AP1052A (en)	2002-03-21
DK0839039T3 (da)	2004-03-08
HK1010494A1 (en)	1999-06-25
PL324553A1 (en)	1998-06-08
HUP9900299A2 (hu)	1999-09-28
GB9514842D0 (en)	1995-09-20
JP3922392B2 (ja)	2007-05-30
EP0839039B2 (de)	2007-06-06
CN1195986A (zh)	1998-10-14
MA23942A1 (fr)	1997-04-01
MY141373A (en)	2010-04-16
NO980240D0 (no)	1998-01-19
AP9801177A0 (en)	1998-01-31
OA10652A (en)	2002-09-18
SI0839039T2 (sl)	2007-10-31
DZ2074A1 (fr)	2002-07-22
DE69630603T3 (de)	2008-01-03
PE16098A1 (es)	1998-04-16
ES2208757T5 (es)	2007-12-16
ZA966148B (en)	1998-01-19
SK284117B6 (sk)	2004-09-08
CN1117567C (zh)	2003-08-13
DK0839039T4 (da)	2007-10-08
BG64076B1 (bg)	2003-12-31
SI0839039T1 (en)	2004-04-30
DE69630603D1 (de)	2003-12-11
CA2445678A1 (en)	1997-02-06
CZ294110B6 (cs)	2004-10-13

Legal Events

Date

Code

Title

Description

2004-07-15

UEP

Publication of translation of european patent specification

Ref document number: 0839039

Country of ref document: EP

2007-11-15

UEP